How to Optimize BPH Treatment: From Evidence to Practice

The α1A-AR selectivity profile of silodosin, as revealed by receptor-binding studies, likely explains the compound's low activity in vascular tissues and its high efficacy in prostate tissue. This selectivity contributes to the drug's low vascular effects and high uroselectivity observed in animal models. These findings have been corroborated by numerous clinical trials, which demonstrate that silodosin has a rapid onset of action and sustained efficacy for treating LUTS due to BPH, all while maintaining an excellent cardiovascular safety profile.

Silodosin is efficacious for the initial management of patients with LUTS. Silodosin has a good cardiovascular safety profile and can be considered an option in PH/LUTS patients with cardiovascular comorbidities.

It seems to be especially beneficial in patients with nocturia alone or presenting with the symptomatic trial nocturia-frequency-incomplete emptying. Patients on PDE5-Is treatment can be safely managed with silodosin. Preliminary results seem to  demonstrate a potential role of silodosin in the treatment of chronic prostatitis/chronic pelvic pain syndrome and to facilitate ureteral stone passage, as well.